Cite

    Hagop M Kantarjian et al.. “Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.” Lancet, vol. 5, no. 3, 2018, pp. e117–e126. http://access.bl.uk/ark:/81055/vdc_100057442708.0x000001